Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monofer versus Ferinject for FGF23 and bone metabolism in chronic kidney disease with iron deficiency
2019-004370-26Phase 4Unknown
- Sponsor
- Hull University Teaching Hospitals
- Start
- Dec 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in iron deficiency anemia (IDA) and chronic kidney disease (CKD) comparing Monofer arm with Ferinject arm (2 arms). Status: unknown.
02
Drugs
ferric derisomaltoseferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2019-004370-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004370-26.